Active substance |
Metreleptine |
Holder |
Amryt Pharmaceuticals DAC |
Statut |
Running |
Indication |
Treatment of patients with generalized lipodystrophy or patients with partial lipodystrophy and uncontrollable metabolic disorders. |
Public documents |
|
Last update |
20/03/2023 |
Myalepta
Last updated on 13/02/2024